{
  "ticker": "JAZZ",
  "company_name": "Jazz Pharmaceuticals",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02953548",
      "title": "Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Infantile Spasms",
      "start_date": "2017-04-24",
      "completion_date": "2018-05-07",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT07233239",
      "title": "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Focal Seizures",
      "start_date": "2025-11-26",
      "completion_date": "2027-11-29",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT02053272",
      "title": "A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetes Mellitus, Type 2",
      "start_date": "2014-02",
      "completion_date": "2016-02",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT05260528",
      "title": "CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Acute Myeloid Leukemia",
      "start_date": "2023-05-03",
      "completion_date": "2027-10",
      "enrollment": 0,
      "sponsor": "Centre Hospitalier Universitaire de Nice"
    },
    {
      "nct_id": "NCT00106860",
      "title": "A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Anxiety Disorder",
      "start_date": "2005-03",
      "completion_date": "2006-03",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT05024552",
      "title": "Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia With FLT3/ITD Mutation",
      "start_date": "2022-02-25",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute"
    },
    {
      "nct_id": "NCT00389428",
      "title": "Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hematologic Neoplasms",
      "start_date": "2006-09",
      "completion_date": "2009-12",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT04943952",
      "title": "JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT00272948",
      "title": "Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Hepatic Veno-Occlusive Disease",
      "start_date": "2005-12",
      "completion_date": "2009-07",
      "enrollment": 0,
      "sponsor": "European Society for Blood and Marrow Transplantation"
    },
    {
      "nct_id": "NCT05656248",
      "title": "Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Myeloid Neoplasm",
      "start_date": "2023-01-17",
      "completion_date": "2028-08",
      "enrollment": 0,
      "sponsor": "St. Jude Children's Research Hospital"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 13,
      "PHASE1": 8,
      "PHASE2": 18,
      "": 6,
      "PHASE2, PHASE3": 1,
      "PHASE1, PHASE2": 2,
      "NA": 1,
      "PHASE4": 1
    },
    "by_status": {
      "COMPLETED": 27,
      "RECRUITING": 8,
      "APPROVED_FOR_MARKETING": 1,
      "ACTIVE_NOT_RECRUITING": 3,
      "UNKNOWN": 1,
      "NOT_YET_RECRUITING": 1,
      "TERMINATED": 5,
      "NO_LONGER_AVAILABLE": 2,
      "WITHDRAWN": 2
    },
    "active_trials": 11,
    "completed_trials": 27,
    "conditions": [
      "Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)",
      "Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma",
      "Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
      "Acute Myelogenous Leukemia, Myelodysplastic Syndrome",
      "Acute Myeloid Leukemia",
      "Acute Myeloid Leukemia With FLT3/ITD Mutation",
      "Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia",
      "Acute Myeloid Leukemia, Myeloid Neoplasm",
      "Adenovirus",
      "Adenovirus Disease",
      "Anxiety Disorder",
      "Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression",
      "Daytime Sleepiness",
      "Diabetes Mellitus, Type 2",
      "Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma",
      "Extensive-stage Small-cell Lung Cancer",
      "Fibromyalgia",
      "Focal Seizures",
      "Fragile X Syndrome",
      "Gastrointestinal Malignancies",
      "Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma",
      "HER2+/HR+ Breast Cancer",
      "HER2-expressing Cancers",
      "HER2-positive Breast Cancer, Breast Cancer",
      "Healthy Participants",
      "Hematologic Neoplasms",
      "Hepatic Impairment",
      "Hepatic Veno-Occlusive Disease",
      "Infantile Spasms",
      "Lennox-Gastaut Syndrome",
      "Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia",
      "Myeloid Neoplasm",
      "Narcolepsy With Cataplexy",
      "Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma, Endometrial",
      "Obstructive Sleep Apnea, Excessive Sleepiness",
      "Oral Mucositis",
      "Ovarian Cancer",
      "Pain, Advanced Cancer",
      "Pain, Peripheral Neuropathy",
      "Protein Losing Enteropathy",
      "Schizophrenia, Schizophrenia-related Psychotic Disorder",
      "Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome",
      "Severe Hepatic Veno-Occlusive Disease",
      "Spasticity With Multiple Sclerosis"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:10.306156",
    "search_query": "Jazz Pharmaceuticals",
    "url": "https://clinicaltrials.gov/search?term=Jazz+Pharmaceuticals"
  }
}